← Eichor
Condition: Refractory Lupus Nephritis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Refractory Lupus Nephritis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
Phase 1 · 1 location(s) · Nanjing IASO Biotechnology Co., Ltd. · NCT07109986A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Phase 1/Phase 2 · 18 location(s) · AstraZeneca · NCT06897930Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06585514A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT06497387Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children
Phase 3 · 1 location(s) · Guangzhou Women and Children's Medical Center · NCT06904729Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
NA · 1 location(s) · Lingli Dong · NCT06277427Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT06497361An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236762A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07123519Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947473A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · 101 location(s) · Novartis Pharmaceuticals · NCT06581198Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06350110Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
NA · 1 location(s) · Tongji Hospital · NCT06902844US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06653556CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
EARLY_Phase 1 · 1 location(s) · He Huang · NCT06785519CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947460A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06943937A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Phase N/A · 1 location(s) · Kyverna Therapeutics · NCT07403188A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523542Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Phase 2 · 12 location(s) · Autolus Limited · NCT07053800NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
Phase 1 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06676631
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.